Abstract Submission Deadline: August 4, 2026

Don’t miss your chance to submit Abstracts for the 2027 ISAKOS Congress being offered live in Sydney, Australia, May 30-June 2, 2027.

Abstracts will be considered for in-person podium presentations and electronic and in-person posters. In addition, exceptional abstracts may be submitted for consideration for ISAKOS Awards for outstanding clinical or laboratory research. These awards will be presented at Congress in Sydney.

Submit an Abstract Instructions for submitting an abstract:

Log-in using the presenting author’s email and password for ISAKOS. If a record does not exist for the presenting author, you will be prompted to create a new record. Complete contact information for the presenting and other authors, including the institution of research. Complete the American Food and Drug Administration (FDA) Statement and Copyright License Agreement on behalf of all authors. Enter the plain abstract text in the provided text box. Please note, graphics and tables are not accepted. There is a maximum of 500 words for the abstract summary. Once the abstract is submitted by the presenting author, any other authors will be notified to complete their disclosures with ISAKOS. Abstracts will not be reviewed until ALL author disclosures are completed.

Abstract Review Following the submission deadline, all abstracts are blindly reviewed by committees of qualified orthopaedic surgeons.

Notification of Results The presenting author will receive a letter of acceptance or rejection via email for the abstract by December 30, 2026.

Abstract Submission Guidelines Author warranty: Persons submitting an abstract to ISAKOS do so with the understanding that they and all the authors listed on the abstract will abide by the guidelines, conditions, deadlines, policies, and decisions of the ISAKOS Board of Directors and Congress Program Committee.

The deadline for abstract submission is August 4, 2026, at 11:59 pm Pacific Daylight Time. Abstracts will not be accepted after that time. Abstracts must be submitted from the ISAKOS account of the Presenting Author. Authors do not have to be ISAKOS members to submit an abstract. There is no limit to the number of abstracts that can be submitted for consideration; however, each presenting author will be limited to no more than two paper presentations during the ISAKOS Congress. If the abstract is accepted for podium presentation, the presenting author must speak in English and be prepared to answer questions from the audience in English. All presenters, co-authors, and faculty members who attend the Congress are expected to register for the meeting and pay all registration and travel costs. No exceptions are made. If attendance is dependent on outside funding, please secure financial assistance before submitting an abstract. Abstracts are only accepted for consideration via the online abstract application form. Abstracts submitted in any other fashion will not be considered. Abstracts must be original and must not have been published or presented at any other meeting prior to the ISAKOS 2027 Congress. The ISAKOS Program Committee will make final decisions on the abstract presentation format. Presenting authors and co-authors must complete a Financial Disclosure Statement, as well as an American Food and Drug Administration statement within the abstract application. Although ISAKOS is an international society, it receives continuing medical education accreditation and is planned and implemented in accord with the essential areas and policies of the Accreditation Council for Continuing Medical Education (ACCME). Presenting authors must complete a Copyright License Agreement so the chosen abstracts can be published by ISAKOS. Channels may include the ISAKOS and Journal of ISAKOS websites. Abstract text is a maximum of 500 words. Abstract Grading Criteria Abstracts are graded on a scale from 0.0 to 12.0 (12.0 being the best) based on the following:

Scientific Merit (0-6, with 6 points max) Is the problem clearly stated? Are the statistics sound? Are there adequate numbers of subjects? How is the methodology (e.g., presence of controls, prospective vs. retrospective design)? Is the abstract clear / well written and are the results clear? Are the conclusions supported by the results? Originality of Project (0-2 points) Clinical Usefulness (0-2 points) Level of Interest to ISAKOS Members (0-2 points)

Learn more about the abstract categories and ISAKOS awards:

View Abstract Primary

Awards